• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

$10 Sovaldi on Sale in Bangladesh

Article

March 12. 2015.

Incepta Pharmaceuticals has introduced a version of Gilead's hepatitis C treatment, Sovaldi, at $10 a pill in Bangladesh, Bloomberg reports. The drug sells for $1,000 a pill in the United States.

Incepta doesn’t have a license from Gilead - Bangladesh is one country, along with Thailand, Malaysia and Morocco, where Sovaldi isn’t patented - but the company is marketing the treatment at about $900 for 12 weeks, the same price as Gilead is offering its branded version of the drug in India.

Bloomberg.

Recent Videos
Related Content
Rudy Kuhn

The Future of Digital Twins: Q&A with Rudy Kuhn

Mike Hollan
July 25th 2024
Article

The lead transformation evangelist at Celonis discusses how digital twins are becoming more prominent in the pharma industry.

Fitterfly

Fitterfly Announces Home Digital Therapeutic That Uses AI to Analyze Images of Meals

Mike Hollan
July 22nd 2024
Article

The AI-powered feature will provide detailed nutritional information based on photos of food taken by users.

Abid Rahman

AI’s Role in Drug Launches, Operations, and Drug Pricing: Q&A with Abid Rahman

Mike Hollan
July 16th 2024
Article

EVERSANA’s senior vice president of innovation discusses how the technology has been implemented in various areas of the pharmaceutical industry.

Dea Belazi

Transforming Patient Care Management: Q&A with Dea Belazi

Mike Hollan
July 12th 2024
Article

The AscellaHealth CEO discusses how new technologies are increasing the options in patient care.

Dr. Jo Varshney

Artificially Discovering New Molecules and Indications: Q&A with Dr. Jo Varshney

Mike Hollan
July 11th 2024
Article

Dr. Varshney discusses how AI is being used to sort data and discover new molecules and indications for existing drugs.

Jon Koch, CEO, Avalere Health.

Can Data and AI Deliver Whole-Person Health?

Jon Koch
July 9th 2024
Article

Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.